The NHLBI Division of Extramural Research Activities (DERA) is pleased to announce the addition of Dr Lawrence Mahan, as the Director of the Office of Translational Alliances and Coordination (OTAC). Dr. Mahan’s professional experience spans academia, government and industry in both basic and applied biomedical research. Additionally it includes global business and strategic alliance development, strategic planning, technology evaluation, entrepreneurship guidance, and consulting on platform technology development in the life sciences.
Most recently Dr. Mahan served as Director of Innovation and Business Development for Children’s National Medical Center and its research institutes, the Children’s Research Institute and the Sheikh Zayed Institute for Pediatric Surgical Innovation, where he managed intellectual property, strategic business alliance development and the advancement of academic entrepreneurship.
Prior to joining CNMC, Dr. Mahan led business development teams at Maryland’s Department of Business & Economic Development as Director of Biosciences & Advanced Technologies. As Senior Strategy Advisor to the Department and the Office of the Governor, he co-authored the State’s 10 year $1.3 billion Strategic Plan for Life Sciences and was the principal architect and first Executive Director of the Maryland Biotechnology Center - a $4 million Governor’s initiative providing dedicated entrepreneur resources and business services to the State’s bioscience entrepreneurs. Other responsibilities included investment diligence for the Maryland Venture Fund and its advanced/biotechnology portfolio, federal lab networking, and policy and legislation development.
Dr. Mahan was formerly a founding partner of an emergent biotechnology company based in Canada, and earlier in his research career was Principal Investigator and Unit Head, Section on Molecular Neuroscience, at the National Institute of Neurological Disorders & Stroke. He is an International lecturer and author of over 100 published articles & abstracts, and holds four U.S. patents.
In his new role Dr. Mahan will lead and coordinate NHLBI efforts to enhance translational technology development, for the improvement of the diagnosis, treatment, and prevention of cardiovascular, lung, and blood diseases and sleep disorders.